<DOC>
	<DOCNO>NCT02991898</DOCNO>
	<brief_summary>This single center pilot study non-myeloablative umbilical cord blood transplant treatment hematological malignancy single infusion T regulatory ( Treg ) give shortly umbilical cord blood transplantation support ultra-low dose ( ULD ) IL-2 4 week . The goal study demonstrate feasibility safety give ULD IL-2 support vivo Treg survival help design future large scale study .</brief_summary>
	<brief_title>Treg Cell With IL-2 Suppress aGVHD Umbilical Cord Blood Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Disease Criteria : Acute Leukemias : Must remission morphology ( ≤5 % blast ) . . Also small percentage blast equivocal marrow regeneration versus early relapse acceptable provide associate cytogenetic marker consistent relapse . Acute Lymphoblastic Leukemia ( ALL ) second great CR ; CR1 unable tolerate consolidation chemotherapy due chemotherapyrelated toxicity ; CR1 highrisk ALL . High risk ALL define one following : Evidence high risk cytogenetics ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) , MLL rearrangement , IKZF1 30 year age old diagnosis White blood cell count great 30,000/mcL ( BALL ) great 100,000/mcL ( TALL ) diagnosis CNS leukemia involvement course disease Slow cytologic response ( &gt; 10 % lymphoblasts bone marrow Day 14 induction therapy ) Evidence persistent immonophenotypic molecular minimal residual disease ( MRD ) end induction consolidation therapy Acute Myelogenous Leukemia ( AML ) relate precursor neoplasm : 2nd great complete remission ( CR ) ; first complete remission ( CR1 ) patient &gt; 60 year old ; CR1 ≤ 60 year old NOT consider favorablerisk . Favorable risk define one following : ( 8,21 ) without cKIT mutation inv ( 16 ) ( 16 ; 16 ) without cKIT mutation Normal karyotype mutate NPM1 wild type FLTITD Normal karyotype double mutate CEBPA Acute prolymphocytic leukemia ( APL ) first molecular remission end consolidation Biphenotypic/Undifferentiated/Prolymphocytic Leukemias first subsequent CR , adult Tcell leukemia/lymphoma first subsequent CR Burkitt 's Lymphoma CR2 subsequent CR Natural Killer Cell Malignancies Chronic Myelogenous Leukemia : type except refractory blast crisis . Chronic phase patient must fail least two different tyrosinekinase inhibitor ( TKIs ) , intolerant available TKIs T315I mutation . Myelodysplastic Syndrome : IPSS INT2 High Risk ; RIPSS High Very High ; WHO classification : RAEB1 , RAEB2 ; Severe Cytopenias : ANC &lt; 0.8 , Anemia thrombocytopenia require transfusion ; Poor poor risk cytogenetics base IPSS RIPSS definition ; therapyrelated MDS . Blasts must &lt; 5 % bone marrow aspirate morphology . If ≥5 % blast , patient require chemotherapy cytoreduction &lt; 5 % blast prior transplantation . LargeCell Lymphoma , Hodgkin Lymphoma Multiple Myeloma chemotherapy sensitive disease fail patient ineligible autologous transplant . Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma ( CLL/SLL ) , Marginal Zone BCell Lymphoma , Follicular Lymphoma , progress within 12 month achieve partial complete remission . Patients remission last &gt; 12 month eligible least two prior therapy . Patients bulky disease consider debulking chemotherapy transplant . Patients refractory disease eligible , unless bulky disease estimate tumor double time le one month . Lymphoplasmacytic Lymphoma , MantleCell Lymphoma , Prolymphocytic Leukemia eligible initial therapy chemotherapy sensitive . Patients must undergone autologous transplant ≤ 12 month prior transplant study receive multiagent immunosuppressive chemotherapy within 3 month preparative regimen . Must ≥18 , &lt; 70 year age available medically suitable 7/8 8/8 HLA match sibling donor , consider HLA A , B , C DRB1 patient ≥ 70 ≤ 75 year age may eligible CoMorbidity score ≤ 2 . ( http : //www.qxmd.com/calculateonline/hematology/hctci ) UCB unit ( ) compose graft select accord current University Minnesota umbilical cord blood graft selection algorithm 3rd cord blood unit use source manufacture Treg product . This UCB unit must match 46/6 patient , consider HLAA , B antigen level DRB1 allele level . Karnofsky performance status ≥ 70 % Adequate organ function define : Renal : creatinine ≤ 2.0 mg/dL , &gt; 1.2 mg/dL must eGFR ≥ 40 Hepatic : bilirubin , AST/ALT , ALP ≤ 5 x upper limit normal , Pulmonary function : DLCO , FEV1 , FVC ≥ 40 % predict , absence O^2 requirement Cardiac : Absence decompensated congestive heart failure , uncontrolled arrhythmia leave ventricular ejection fraction ≥ 40 % . Sexually active female childbearing potential male partner childbearing potential must agree Voluntary write informed consent sign Untreated active infection History HIV infection Pregnant breast feeding . The agent use study may teratogenic fetus information excretion agentsinto breast milk . Females childbearing potential must blood test urine study within 14 day prior registration rule pregnancy Prior allogeneic transplantation Less 3 month myeloablative condition autologous transplantation ( applicable ) Evidence progressive disease image modality biopsy persistent PET activity , though possibly relate lymphoma , exclusion criterion absence CT change indicate progression . CML blast crisis Large cell lymphoma , mantle cell lymphoma Hodgkin disease progress salvage therapy . Active central nervous system malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Acute Leukemias</keyword>
	<keyword>Burkitt 's Lymphoma</keyword>
	<keyword>Natural Killer Cell Malignancies</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Large-Cell Lymphoma , Hodgkin Lymphoma , Multiple Myeloma</keyword>
	<keyword>Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma , Marginal Zone B-Cell Lymphoma , Follicular Lymphoma :</keyword>
	<keyword>Lymphoplasmacytic Lymphoma , Mantle-Cell Lymphoma Prolymphocytic Leukemia</keyword>
</DOC>